Drug Research
Ranbaxy launches cholesterol reducing drug in Australia
Ranbaxy Australia, a subsidiary of Ranbaxy Laboratories, has introduced Atorvastatin 10mg, 20mg, 40mg and 80mg tablets after receiving approval from Therapeutic Goods Administration (TGA)...
Drug Research
APP Pharmaceuticals receives marketing approval for Methotrexate Injection
APP Pharmaceuticals, a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals, has received FDA approval to market preservative-free Methotrexate Injection, USP. ...
Drug Research
La Jolla buys GCS-100 rights from Solana
La Jolla Pharmaceutical Company has acquired global development and commercialization rights to GCS-100 from Solana Therapeutics. GCS-100 is an inhibitor...
Drug Research
Novartis receives Morrison & Foerster advice on Camurus deal
The global law firm, Morrison & Foerster has advised Novartis to sign an exclusive collaboration, option and license agreement with Camurus, a Swedish research-based...
Drug Research
Mymetics regains intra-nasal influenza vaccine from Solvay
Mymetics, a developer of next-generation preventative vaccines, has regained its intra-nasal influenza vaccine from Solvay.Mymetics has provided license of its intra-nasal flu vaccine, under which...
Drug Research
The Medicines Company introduces new Cleviprex formulation
The Medicines Company has launched a new twelve hour formulation for the FDA approved Cleviprex Injectable Emulsion.Cleviprex is an intravenous dihydropyridine calcium channel blocker, which...
Drug Research
Theraclone doses first patient in Phase 1 TCN-032 drug trial
Theraclone Sciences has dosed first patient in a randomized, double-blind, dose-escalation Phase 1 trial investigating TCN-032 as a treatment for influenza A virus. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.